Review
doi: 10.1056/NEJMct0807960.
Treatment of non-small-cell lung cancer with erlotinib or gefitinib
Affiliations
- PMID: 21388312
- DOI: 10.1056/NEJMct0807960
Item in Clipboard
Review
Treatment of non-small-cell lung cancer with erlotinib or gefitinib
N Engl J Med.
.
Abstract
A 64-year-old woman receives the diagnosis of metastatic non-small-cell lung cancer (NSCLC), which has progressed during treatment with carboplatin, paclitaxel, and bevacizumab. Erlotinib therapy is recommended.
Comment in
-
Erlotinib or gefitinib for non-small-cell lung cancer.N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918. N Engl J Med. 2011. PMID: 21675909 No abstract available.
-
Erlotinib or gefitinib for non-small-cell lung cancer.N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918. N Engl J Med. 2011. PMID: 21675910 No abstract available.
Similar articles
-
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3. Cochrane Database Syst Rev. 2021. PMID: 33734432 Free PMC article.
-
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.
-
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Cochrane Database Syst Rev. 2016. PMID: 27223332 Updated. Review.
-
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).Oncologist. 2010;15(12):1344-51. doi: 10.1634/theoncologist.2010-0257. Epub 2010 Dec 10. Oncologist. 2010. PMID: 21148614 Free PMC article. Clinical Trial.
-
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.Clin Lung Cancer. 2004 Dec;6 Suppl 1:S24-9. doi: 10.3816/clc.2004.s.011. Clin Lung Cancer. 2004. PMID: 15638954 Review.
Cited by
-
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.NPJ Precis Oncol. 2024 Feb 23;8(1):46. doi: 10.1038/s41698-024-00542-9. NPJ Precis Oncol. 2024. PMID: 38396251 Free PMC article.
-
Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib.Cureus. 2023 Nov 1;15(11):e48122. doi: 10.7759/cureus.48122. eCollection 2023 Nov. Cureus. 2023. PMID: 38046784 Free PMC article.
-
Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors.Transl Oncol. 2024 Jan;39:101826. doi: 10.1016/j.tranon.2023.101826. Epub 2023 Nov 18. Transl Oncol. 2024. PMID: 37984256 Free PMC article.
-
Phenethyl isothiocyanate inhibits metastasis potential of non-small cell lung cancer cells through FTO mediated TLE1 m6A modification.Acta Pharmacol Sin. 2024 Mar;45(3):619-632. doi: 10.1038/s41401-023-01178-4. Epub 2023 Oct 17. Acta Pharmacol Sin. 2024. PMID: 37848553
-
Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice.Cancers (Basel). 2023 Aug 30;15(17):4345. doi: 10.3390/cancers15174345. Cancers (Basel). 2023. PMID: 37686621 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
